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a b s t r a c t
Emerging and well-known viral diseases remain one the most important global public health threats. A
better understanding of their pathogenesis and mechanisms of transmission requires animal models
that accurately reproduce these aspects of the disease. Here we review the role of ferrets as an animal
model for the pathogenesis of different respiratory viruses with an emphasis on inﬂuenza and
paramyxoviruses. We will describe the anatomic and physiologic characteristics that contribute to the
natural susceptibility of ferrets to these viruses, and provide an overview of the approaches available to
analyze their immune responses. Recent insights gained using this model will be highlighted, including
the development of new prophylactic and therapeutic approaches. To provide decision criteria for the
use of this animal model, its strengths and limitations will be discussed.
& 2015 Elsevier Inc. All rights reserved.
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Ferrets as experimental animals
Domestic ferrets (Mustela putorius furo) are small carnivores
belonging to the Mustelidae family. Their closest wild relatives are
wild European ferrets (M. putorius), European polecats (M. furo)
and the steppe polecat (M. eversmannii), and interbreeding among
these species produces fertile offspring, illustrating the close
relationship (Lewington, 2007). Due to their relatively small size
and their similarity to humans with respect to aspects of their
anatomy, physiology, and metabolism, they are increasingly con-
sidered an alternative to larger animal models such as dogs and
non-human primates (Clingerman et al., 1991). Ferrets are avail-
able from different commercial breeders, some of which are even
offering speciﬁc pathogen free (SPF) animals. Seronegative ani-
mals, while of particular interest for the infectious disease com-
munity, are difﬁcult to maintain due to the natural susceptibility of
ferrets for human respiratory viruses. Breeders offer pre-testing of
animals prior to purchase and use HEPA-ﬁltered transport cages to
minimize risk of exposure during shipping, but the serostatus of
all animals has to be veriﬁed after arrival. In addition, personal
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Fig. 1. Examples of different cage types for ferret housing. Longterm free-range housing in same sex groups. Environmental enrichment like hammocks, tubes, and
additional levels for climbing are provided (A, B). During ongoing experiments the animals are housed in pairs in different cage types connected by tubes or openings in
separating walls (C, D).
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Fig. 2. Large volume blood collection sites. The anterior vena cava (A, B) and the internal jugular vein (C) allow collection of larger blood volumes.
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Fig. 3. Viruses investigated in ferrets. Viruses from different families discussed in this review that have been studied in ferrets.
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protective equipment such as N95 masks or powered air purifying
respirators (PAPRs) should be worn for all interactions with the
animals to prevent accidental exposure by infected staff.
The animals are social and should be housed in same sex
groups whenever possible (Fig. 1A and B). Many of the standard
rabbit caging systems can be used to house ferrets during experi-
ments (Fig. 1C and D). The spacing of the grid walls and food
receptacles may have to be adapted to prevent escape, and hiding
places such as tubing or tunnel, hammocks, or nesting boxes have
to be provided (Ball, 2002). Because of their value for pathogen-
esis studies with viruses requiring high containment, different
individually ventilated cage (IVC) systems have been also been
developed. An adult female ferret weighs 700–1000 g, while males
weigh 1400–2000 g, thus allowing repeat blood sampling at
volumes sufﬁcient for immunological analyses over the course of
an infection (Bixler and Ellis, 2004). While small blood samples
can be obtained from the tail or leg veins, larger volumes required
for the isolation of peripheral blood mononuclear cells are best
collected from the anterior vena cava (Fig. 2A and B) or the
internal jugular vein (Fig. 2C). The sexual weight dimorphism
together with the requirement for inducing ovulation in female
ferrets in estrus has led many researchers to preferentially use
males (Fox, 1998; Sherrill and Gorham, 1985).
Following the fortuitous discovery of the natural susceptibility
of ferrets to human inﬂuenza viruses in the 1930s (Smith et al.,
1933), they were found to reproduce the human course of disease
of a number of human respiratory viruses including respiratory
syncytial virus (RSV), parainﬂuenzaviruses (PIV), and severe acute
respiratory syndrome (SARS)-coronavirus (Fig. 3). In addition to
the presence of the respective receptors, the fact that anatomic
proportions of the ferret upper and lower respiratory tracts, the
density of submucosal glands in the bronchial wall and the
number of generations of terminal bronchioles are all reproduce
the situation in the human respiratory tract likely contributes to
this effect (Johnson-Delaney and Orosz, 2011; Robinson et al.,
1986). With technical developments enabling infection via the
ocular route or by aerosol, the impact of the inoculation route and
volume on pathogenesis have been increasingly recognized (Belser
et al., 2014, 2012; Bodewes et al., 2013; Kreijtz et al., 2013; Moore
et al., 2014). For most studies however, the animals are inoculated
intranasally with volumes ranging from 0.1 to 1 ml.
Inﬂuenza virus
In the context of infectious disease research, ferrets are most
widely known as model for the study of inﬂuenza viruses, which
belong to the Orthomyxoviridae family (Palese and Shaw, 2007).
Inﬂuenza A, and to a lesser extent inﬂuenza B, viruses cause annual
epidemics with an estimated 250,000–500,000 deaths worldwide.
While humans are the only natural reservoir for inﬂuenza B,
inﬂuenza A infects a broad range of avian and mammalian species
with aquatic birds acting as principal reservoir. Among livestock,
infections in poultry and pigs have the greatest economic impact, but
horses, and more recently dogs, can also be affected. Avian and swine
inﬂuenza A viruses are of particular public health relevance because
their close contact with humans provides multiple opportunities for
interspecies adaptation and transmission (Palese and Shaw, 2007).
Inﬂuenza A viruses are grouped into different subtypes accord-
ing to the antigenicity of their surface glycoproteins, which are the
principal targets of the neutralizing antibody response (Gerhard,
2001; Palese and Shaw, 2007). So far, 18 hemagglutinin (HA, H1–
H18) and 11 neuraminidase (NA, N1–N11) subtypes have been
identiﬁed (Tong et al., 2012, 2013). Introduction of a new inﬂuenza
A subtype into the human population can result in a pandemic
with increased morbidity and mortality (Belser et al., 2009;
Johnson and Mueller, 2002). Avian inﬂuenza viruses are further
classiﬁed in low pathogenic (LPAIV) and highly pathogenic avian
inﬂuenza viruses (HPAIV), according to their HA cleavage site:
LPAIV HAs carry a monobasic cleavage site, which can only be
activated by proteases present in the avian respiratory tract, while
HPAIV HAs are activated by subtilisin-like proteases present in
every cell due to their polybasic cleavage site (Bertram et al., 2010).
Ferrets became the animal model of choice for inﬂuenza research
when the ﬁrst isolation of an inﬂuenza virus succeeded in this
species (Smith et al., 1933), and they have made remarkable
contributions to our understanding of inﬂuenza biology ever since.
In addition to being naturally susceptible to human inﬂuenza A
strains, the clinical course of disease in ferrets reproduces key aspects
of human disease including fever, lethargy and signs of upper and
sometimes lower respiratory infection (Bouvier and Lowen, 2010;
Smith and Sweet, 1988). The similar inﬂuenza receptor distribution in
the human and ferret respiratory system likely represents an
important contributing factor: in the upper respiratory tract of both
species, there is a high density of alpha 2,6-linked sialic acids
(SAα2,6), while SAα2,6 as well as alpha 2,3-linked sialic acids
(SAα2,3) are present in the lower respiratory tract (Shinya et al.,
2006; van Riel et al., 2007). As seen in adult human patients with
uncomplicated inﬂuenza, infection of ferrets with seasonal H1N1 and
H3N2 strains, which preferentially bind to SAα2,6, results in a mild to
moderate disease characterized by extensive infection of the upper
respiratory tract with limited spread to the lung (Huang et al., 2011;
van den Brand et al., 2012). In contrast, highly pathogenic inﬂuenza
viruses, which have a higher afﬁnity to SAα2,3, are always associated
with severe pneumonia and widespread infection throughout the
lung (Belser et al., 2009; Kumlin et al., 2008; Nicholls et al., 2008;
Shinya et al., 2006; van Riel et al., 2007), and in the case of certain
strains also lead to neurologic and gastrointestinal involvement
(Gambotto et al., 2008). The assessment of the reconstructed pan-
demic H1N1 1918 virus in ferrets not only demonstrated the high
virulence of this historic virus compared to a seasonal human H1N1
strain (Taubenberger et al., 1997; Tumpey et al., 2005), but also
revealed that two amino acid changes in the HA protein were
sufﬁcient to switch the receptor speciﬁcity from SAα2,6 to SAα2,3
and abolish respiratory droplet transmission (Tumpey et al., 2007),
illustrating the important role of receptor speciﬁcity in inﬂuenza
pathogenesis.
The similarity in inﬂuenza susceptibility between humans and
ferrets is increasingly exploited to gain insights into the transmis-
sibility and virulence of new isolates. Human-adapted seasonal
inﬂuenza viruses spread through direct or indirect contact or
respiratory droplets (Brankston et al., 2007), while infections with
avian viruses are usually associated with close contact to infected
poultry and are rarely transmitted. Transmissibility assessments of
different HPAIs in ferrets have conﬁrmed the poor transmissibility
observed in the ﬁeld (Maines et al., 2006). However, there is great
concern that one of these viruses acquires the capacity for aerosol
spread and causes a pandemic (Matrosovich et al., 2000; Stevens
et al., 2008). Characterization of transmission determinants using
genetically modiﬁed H5N1 viruses revealed that only ﬁve amino
acid changes in the HA, PB1, and PB2 proteins were sufﬁcient to
enable efﬁcient respiratory droplet transmission between ferrets
(Herfst et al., 2012; Imai et al., 2012; Linster et al., 2014). Most of
these mutations had already been described to play an important
role in inﬂuenza virulence in ferrets and mice by either affecting
replication efﬁciency or altering virus tropism (Chen et al., 2007;
Hatta et al., 2001; Maines et al., 2011; Shinya et al., 2004). In
contrast to HPAI H5N1, the recently emerged human H7N9 isolates
display a natural afﬁnity for both SAα2,6 and SAα2,3 receptors.
Even though they replicate efﬁciently in the upper and lower
respiratory tract of humans and ferrets, transmission studies have
so far yielded contradictory results ranging from reports of
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efﬁcient airborne transmission over reduced aerosol transmission
compared to seasonal and pandemic H1N1 strains to contact
transmission only (Belser et al., 2013; Richard et al., 2013).
The value of the ferret model to rapidly gauge the virulence of a
newly emerging virus ﬁrst became apparent during the H1N1
2009 pandemic. Evaluation of early isolates indicated an increased
morbidity and higher pathogenicity compared to seasonal H1N1
strains but similar transmission efﬁciency (Maines et al., 2009;
Munster et al., 2009), thereby providing valuable information to
public health ofﬁcials. A large body of work investigating the
pathogenesis and transmissibility of HPAI H5N1, H7N1, and H9N1
strains isolated from human cases or poultry provides a frame-
work for the pandemic risk assessment of new viruses emerging
from the animal reservoir (Kimble et al., 2014; Lipatov et al., 2009;
Maines et al., 2006; Sutton et al., 2014; Yen et al., 2007). Recently,
avian H3N8 inﬂuenza viruses isolated from seals were found to
have naturally acquired mutations known to increase transmissi-
bility, demonstrated increased afﬁnity for mammalian SAα2,6
receptors, and were transmitted via respiratory droplets between
ferrets (Karlsson et al., 2014), suggesting a pandemic potential for
these viruses. This year, a novel highly pathogenic H5N8 virus was
isolated from outbreaks in poultry ﬁrst in Korea and China, and
more recently also in Europe and Canada (Fan et al., 2014; Ku et al.,
2014; Wu et al., 2014). The virus causes moderate to severe disease
in ferrets, but so far no avian-to-human transmission has been
observed (Kim et al., 2014). This continued emergence of new
inﬂuenza strains in birds and mammals not only requires active
surveillance but also the need for systematic characterization of
their pandemic potential including pathogenesis studies in ferrets.
Despite the limited availability of ferret-speciﬁc immunological
reagents, investigation of innate host responses based on mRNA
expression levels, either by quantitative real-time RT-PCR or using
a canine microarray, revealed proﬁles similar to those seen in
patients, thereby illustrating the value of this animal model not
only for virulence assessment but also the characterization of host
responses (Cameron et al., 2008; Kang et al., 2011; Maines et al.,
2012; Meunier et al., 2012). While seasonal inﬂuenza strains are
generally associated with a rapid rise and fall of type I and II
interferons and TNFα during the ﬁrst days after infection (Rowe
et al., 2010; Svitek et al., 2008), highly pathogenic H5N1 strains
lead to a more sustained expression of interferon response genes
and higher expression levels of cytokines and inﬂammatory med-
iators in the lungs (Cameron et al., 2008). Since such a hypercy-
tokinemia or cytokine storm is also observed in H5N1 patients (de
Jong et al., 2006; Peiris et al., 2009; To et al., 2001) a more detailed
characterization of the underlying pathomechanism in ferrets,
using newly developed tools and assays and including more det-
ailed kinetics of lymphocyte subsets, hematological parameters
and serum chemistry proﬁles (Belser et al., 2011), may yield inn-
ovative therapeutic approaches.
The ferret model also remains the gold standard for efﬁcacy
assessments of new vaccine strategies and therapeutic approaches.
These studies are usually performed using seronegative animals to
eliminate additional confounding factors, even though this does not
reﬂect the epidemiological situation in the human population, where
most adults have been exposed to at least one, but likely several,
strains of the circulating subtypes (Bodewes et al., 2011; Fonville et al.,
2014; Hoschler et al., 2013). At this time, inactivated inﬂuenza vaccines
and live-attenuated inﬂuenza vaccines (LAIV) are licensed in most
countries (Lambert and Fauci, 2010). While LAIV induce a stronger
immune response in naïve individuals, inactivated vaccines are more
immunogenic in the presence of pre-existing immunity. In the context
of the annual vaccination campaigns, LAIV are thus primarily given to
children and young adults (Rodgers et al., 2015). The potential of LAIV
to induce a broader and more efﬁcient immune response against
newly emerging strains has been investigated extensively. Studies in
ferrets demonstrated that a recombinant H5N1 LAIV elicited a broad
cross-protection against different H5N1 sublineages (Li et al., 1999;
Suguitan et al., 2006). More recently, it was shown that immunization
with LAIV H7N3 and H7N7 resulted in cross protection against the
newly emerged H7N9 virus (Xu et al., 2013b).
The immunogenicity and extent of cross-protection have also
been investigated for inactivated pandemic vaccines. In general,
whole-virus inactivated vaccines induce robust responses after a
single dose and may even protect against antigenetically mis-
matched viruses (Govorkova et al., 2006; Poland and Sambhara,
2008; Subbarao and Luke, 2007). In contrast, split-virus or subunit
vaccines are less immunogenic, and more than one dose or the
addition of an adjuvant are required to protect naïve individuals
(Bresson et al., 2006; De Groot et al., 2013; Duan et al., 2014; Lin
et al., 2006). The development of safe and efﬁcacious adjuvants is
of great relevance in the context of pandemic preparedness, since
the use of adjuvants reduces the amount of antigen needed per
dose (Clegg et al., 2014; Onishi et al., 2014). In addition, the
development of adjuvanted seasonal vaccines is considered for
seniors, who often respond poorly to the currently used non-adju-
vanted inactivated vaccines (Ann et al., 2014; van den Brand et al.,
2011).
A comprehensive overview of innovative vaccine approaches
against inﬂuenza is beyond the scope of this review. Among the
most promising candidates are virus-like particles (VLPs) com-
posed of the M1 matrix protein together with the HA and NA
proteins. Intranasal or intramuscular vaccination with such VLPs
containing H5, H7 and H9 proteins, or the H1 protein alone,
induced an immune response against all HAs present and pro-
tected ferrets from challenge with multiple avian inﬂuenza viruses
(Mahmood et al., 2008; Pushko et al., 2011; Ross et al., 2009;
Tretyakova et al., 2013). Different viral vector-based approaches
have also been developed to the clinical trial stage. Among those,
recombinant modiﬁed vaccinia virus Ankara (MVA) expressing
different HA subtypes have demonstrated efﬁcacy in ferrets and
recent in ﬁrst-in-man clinical trials have conﬁrmed the immuno-
genicity in humans (Kreijtz et al., 2014, 2010; Rimmelzwaan and
Sutter, 2009). DNA- and more recently RNA-based vaccine candi-
dates have great appeal in a pandemic context, since they can be
produced rapidly and at large scale. DNA vaccines expressing
single or multiple HA proteins alone or in combination with NA
induce protective T and B cell responses in different animal
models, especially in the context of prime-boost regimen with
other vaccine candidates (Bragstad et al., 2011; Lin et al., 2012;
Pillet et al., 2011; Rao et al., 2010; Suguitan et al., 2011). In a ﬁrst
proof-of-concept study, a PR8-HA-expressing RNA vaccine induced
an immune response similar to approved inﬂuenza vaccines in
ferrets and pigs (Petsch et al., 2012), indicating the feasibility
of this approach. However, despite recent progress using in vivo
electroporation or gene guns (Laddy et al., 2008; Yager et al.,
2013), efﬁcient DNA or RNA delivery remains a major obstacle for
the implementation of this technology.
At this time, there are two classes of commercially available
drugs against inﬂuenza, adamantane-derivatives, which inhibit
the M2 ion channel, and neuraminidase inhibitors. In addition,
the viral polymerase inhibitor favipiravir has received regulatory
approval in Japan for use against inﬂuenza in 2014 (Furuta et al.,
2013; Nagata et al., 2014). Early on, ferret studies demonstrated
the rapid emergence of antiviral resistance against adamantanes
and the transmission of drug-resistant strains without loss of
virulence (Herlocher et al., 2003; Sweet et al., 1991), thereby
predicting todays resistance of all circulating seasonal inﬂuenza
strains (Bright et al., 2005; Bright et al., 2006). Nonetheless,
adamantanes may still be useful in the context of a pandemic
strain carrying a non-resistant M segment of animal origin
(Nguyen et al., 2012). Ferret studies also demonstrated the efﬁcacy
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of neuraminidase inhibitors against lethal infection with different
H5N1 strains (Boltz et al., 2008a, 2008b; Govorkova et al., 2007),
which are now an integral part of pandemic preparedness strate-
gies. After the emergence of oseltamivir-resistant strains, studies
in ferrets have been used to characterize the impact of the
mutations involved and to investigate the ﬁtness cost associated
with this resistance (Watanabe et al., 2013). Ferret studies thus
remain an integral part in the development of new prophylactic
and therapeutic strategies against inﬂuenza.
Paramyxoviruses
Henipaviruses
Hendra (HeV) and Nipah (NiV) viruses belong to the genus
Henipavirus within the Paramyxoviridae family. Their natural hosts
are fruit bats of the family Pteropodidae that can be found in
South-East Asia, Australia and Africa (Hayman et al., 2008; Olson
et al., 2002; Young et al., 1996). Infected bats shed the virus in
urine, thereby infecting other species. Transmission to humans
occurs through intermediate hosts like pigs (NiV) and horses
(HeV) (Luby et al., 2009). Ephrin B2, which has been identiﬁed
as the cellular receptor of henipaviruses, is highly conserved and
present on endothelial cells, smooth muscle cells, and neurons
(Gale et al., 2001), and thus thought to contribute to the broad
species and tissue tropism (Bonaparte et al., 2005). In humans, the
Henipavirus case fatality rate is approximately 70%. The disease
starts with inﬂuenza-like symptoms such as fever, dry cough, sore
throat, and lymphadenopathy, often leading to acute respiratory
distress symptom (ARDS) (Hossain et al., 2008). There is a high
incidence of neurologic symptoms and survivors often experience
neurologic sequelae months and even years after the acute
infection (O'Sullivan et al., 1997; Playford et al., 2010; Tan et al.,
2002; Wong et al., 2009).
Ferrets experimentally infected with NiV or HeV develop the
full spectrum of disease seen in humans. First clinical signs occur
6–10 days after infection, starting with fever, coughing, nasal
discharge, shortness of breath, and depression, sometimes fol-
lowed by limb paralysis and meningitis (Bossart et al., 2009;
Pallister et al., 2009, 2011). Comparison of NiV strains isolated
from patients in Bangladesh and Malaysia revealed differences in
the amount of virus shed in oral secretions of infected ferrets,
which may explain the increased human-to-human transmissions
seen during outbreaks in Bangladesh (Clayton et al., 2012). How-
ever, more extensive pathogenesis and transmission studies are
limited by the high containment requirements for the work with
these viruses. A recently generated recombinant HeV expressing
GFP or luciferase from an additional open reading frame retained
the ability to cause fatal disease in ferrets, thus constituting a
valuable tool to directly characterize dissemination and to visua-
lize virus–host interactions (Marsh et al., 2013).
While there is currently no vaccine or antiviral treatment
approved for humans, a HeV vaccine for horses based on soluble
HeV glycoprotein has been available since 2012. Efﬁcacy studies in
ferrets were instrumental in the development of this vaccine
(Bossart et al., 2005; Middleton et al., 2014; Pallister et al., 2011),
and the analogous approach against NiV protected ferrets from
NiV challenge for more than 12 months (Broder et al., 2013;
Pallister et al., 2013). A vesicular stomatitis virus pseudotyped
with the NiV glycoproteins was equally protective in ferrets,
indicating that the development of an efﬁcient and safe vaccine
against these viruses is feasible (Mire et al., 2013). In addition, the
potential of monoclonal antibody treatment has also been demon-
strated in ferrets using a monoclonal antibody, which blocks the
receptor-binding domain of the HeV and NiV G glycoproteins
(Bossart et al., 2009), further validating ferrets as animal model
for these viruses.
Pneumoviruses
Human respiratory syncytial virus (hRSV) and human metap-
neumovirus (hMPV) belong to the Pneumovirinae subfamily in the
Paramyxoviridae family. They are one of the leading causes of
respiratory disease in children worldwide, each year affecting
more than 33 million children under the age of ﬁve as well as
elderly and individuals with pre-existing respiratory conditions
(Falsey et al., 2005; Nair et al., 2010; van den Hoogen et al., 2001).
These viruses are transmitted via respiratory droplets or through
direct contact with respiratory secretions (Hall et al., 1981). The
infection is limited to respiratory epithelial cells (Lotz and Peebles,
2012), and the disease is mostly characterized by coughing,
sneezing and fever. However, newborns, especially prematurely
born infants, can progress to apnea, feeding difﬁculties, and
periodic breathing (Collins and Graham, 2008; Dahlem et al.,
2003; van den Hoogen et al., 2003). In elderly patients, the
infection often leads to pneumonia and chronic pulmonary dis-
ease, asthma, and congestive heart failure (Falsey et al., 2003,
2005). There is currently no vaccine against hRSV or hMPV, and
the only approved antiviral drugs are ribavirin and a humanized
monoclonal antibody directed against the RSV F glycoprotein
(Johnson et al., 1997).
Ferrets are susceptible to hRSV and hMPV infection, and the
viruses replicates to high titers in the nasal tissues (Coates and
Chanock, 1962). However, hMPV-infected ferrets show no signs of
disease (MacPhail et al., 2004). When animals were infected early
in life, hRSV causes acute and chronic changes in the neural
control of the airways that persist long after the virus was cleared
(Colasurdo et al., 1998; Larsen and Colasurdo, 1999). Ferrets were
also used to investigate the potential of recombinant adenoviruses
expressing the RSV fusion and attachment glycoproteins individu-
ally or in combination. After intranasal administration, strong RSV-
speciﬁc antibody responses were observed, and the animals were
protected from subsequent RSV challenge (Hsu et al., 1994). Since
replication in the lung only takes place in infant ferrets (Prince and
Porter, 1976), their use as animal model for pneumovirus patho-
genesis studies has been limited and little is known about the
cellular receptors or mechanisms involved, even though ferrets
reproduce the age-dependent differences in disease severity seen
in humans.
Morbilliviruses
Ferrets are not susceptible to measles virus (MeV), the member
of the Morbillivirus genus infecting humans and certain non-
human primates. However, they are very sensitive to canine
distemper virus (CDV), which infects a broad range of terrestrial
and aquatic carnivores, and the disease reproduces all key ele-
ments seen in MeV-infected patients (Ludlow et al., 2014). Because
of the high degree of genetic, structural, and functional conserva-
tion among morbilliviruses and the consistent course of disease
caused by CDV in ferrets, this model is frequently used to
characterize common morbillivirus pathogenesis mechanisms.
Upon infection with a CDV wild type strain via the respiratory
route, virus can ﬁrst be isolated from peripheral blood mono-
nuclear cells (PBMC) after 2–3 days, and most T and B lymphocytes
in lymphatic organs are CDV-positive within one week (Pillet and
von Messling, 2009). This coincides with a dramatic drop in white
blood cell numbers and the loss of PBMC proliferation activity
upon non-speciﬁc stimulation (von Messling et al., 2003). While
the decrease in white blood cells is seen in all infections, the
extent of inhibition of PBMC proliferation activity and of innate
T. Enkirch, V. von Messling / Virology 479-480 (2015) 259–270 263
immune activation correlates with disease severity (Svitek and
von Messling, 2007). The latter is controlled by the accessory V
protein (Ramachandran et al., 2008; Rothlisberger et al., 2010), and
a recent study in ferrets revealed that inhibition of STAT2 and
mda5 signaling is essential for morbillivirus-mediated interference
with the innate immune response (Svitek et al., 2014). After the
signaling lymphocyte activation molecule (SLAM) was identiﬁed as
morbillivirus immune cell receptor (Tatsuo et al., 2000; Tatsuo
et al., 2001), pathogenesis studies with SLAM-blind viruses, ﬁrst
with CDV in ferrets and then with MeV in macaques, revealed that
immune cell infection is essential for immunosuppression and
clinical disease, thereby conﬁrming the “immune cells ﬁrst”
hypothesis (Leonard et al., 2010; von Messling et al., 2005).
After ampliﬁcation in lymphatic organs, the virus spreads to
epithelial tissues throughout the body. If the immune response is
not sufﬁcient to control and subsequently clear the virus, the loss
of epithelial integrity eventually leads to septicemia and death
within three to ﬁve weeks after infection. The recently identiﬁed
epithelial cell receptor nectin-4 (Muhlebach et al., 2011; Noyce
et al., 2011) has enabled the generation of nectin-4-blind viruses,
which subsequently not only illustrated the importance of epithe-
lial cell infection for clinical disease but also demonstrated that
acute immunosuppression requires immune but not epithelial cell
infection (Frenzke et al., 2013; Sawatsky et al., 2012). Since the
incidence of neuroinvasion in ferrets can reach 100% for some
strains, they have also been used to investigate morbillivirus
neuropathogenesis mechanisms. In addition to the previously
known entry routes via the choroid plexus and small blood
vessels, the anterograde infection along the olfactory nerves was
identiﬁed as an additional entry pathway (Rudd et al., 2006).
Comparative studies with different strains revealed a correlation
with longer disease duration and less severe immunosuppression
(Bonami et al., 2007).
The study of CDV in ferrets as a surrogate for MeV in primates
has also been used to investigate the potential of novel vaccines
and, more recently, an antiviral drug candidate (Krumm et al.,
2014; Rouxel et al., 2009; Welter et al., 2000). The consistent
pathogenesis together with the availability of robust reverse
genetics systems for several vaccine and wild type strains thus
make the CDV-ferret model an attractive system to characterize
virus-host interactions in the context of lethal disease outcome or
survival, and to investigate the impact of interventions at different
stages of disease.
Coronaviruses
In addition to viruses causing a mild upper respiratory tract
infection, the Coronavirinae subfamily also includes members that
lead to severe acute respiratory disease with mortality rates of
around 10% for severe acute respiratory syndrome (SARS)-CoV and
even higher for Middle East respiratory syndrome (MERS)-CoV
(Butler, 2012; Hui et al., 2014). Because of the respiratory tropism,
the susceptibility of ferrets was evaluated. In the case of SARS-CoV,
the virus was found to replicated efﬁciently in the upper and lower
respiratory tract, and the animals developed clinical disease
characterized by nasal discharge, sneezing, fever, and virus shed-
ding including contact transmission to naïve cage mates after
intratracheal infection (Chu et al., 2008; Martina et al., 2003).
However, no clinical signs were seen after intranasal infection in a
different study (Weingartl et al., 2004). This variability may be due
to the route of infection, and the age, gender, and genetics of the
animals are likely additional contributing factors.
In humans, the SARS-CoV tropism reﬂects the distribution of
the cellular receptor angiotensin-converting enzyme (ACE) 2
(Drosten et al., 2003; Li et al., 2003) in lung alveolar epithelial
cells, enterocytes of the small intestine and tubular cells of the
kidney (Ding et al., 2004; Gu et al., 2005; Hamming et al., 2004).
The disease can range from mild respiratory signs to severe
respiratory failure. After incubation period of 2–14 days patients
initially present with inﬂuenza-like symptoms, fever, and cough
that can progress to atypic pneumonia and respiratory failure
(Peiris et al., 2003). The virus can also spread to multiple organs
including the gastrointestinal and urinary tract causing a systemic
disease. Even though it has been shown that ferret ACE2 interacts
efﬁciently the SARS-CoV receptor-binding spike (S) protein
(Zamoto et al., 2006), the tropism of SARS-CoV in ferrets does
not match the receptor distribution (Gramberg et al., 2005), which
may explain the differences in clinical manifestation observed.
Nevertheless, the ferret represents a useful animal model for
the safety and efﬁcacy assessment of SARS-CoV vaccine candidates
and therapeutic approaches. While a MVA-based vaccine expres-
sing the SARS-CoV S protein elicited a strong neutralizing immune
response and protected the animals from disease, inﬂammatory
lesions were found in the liver of the vaccinated animals
(Weingartl et al., 2004). Formalin-inactivated whole-virus vaccines
as well as an S-expressing adenovirus-based vaccine also induced
neutralizing antibodies and no liver pathology was noted, but the
extent of protection varied, indicating that that a combination of
vaccine strategies may be required for effective protection (Darnell
et al., 2007; See et al., 2008). Prophylactic treatment with a
monoclonal antibody reduced the replication of SARS-CoV in the
lungs of infected ferrets up to one thousand-fold and may thus be
useful in protecting contacts thereby limiting the spread of the
disease (ter Meulen et al., 2004).
In the case of MERS-CoV, which also causes a severe pulmonary
disease in humans, similar to SARS-CoV (Zaki et al., 2012), ferrets
were not found to be susceptible. Even though MERS-CoV and
SARS-CoV are both members of the genus Betacoronavirus, they
differ in their receptor usage. MERS-CoV uses dipeptidyl peptidase
(DPP) 4 for cell entry (Raj et al., 2013), which can also be found on
ferret cells, but the sequence differences between the human and
ferret DPP4 protein prevent binding of MERS-CoV (van Doremalen
et al., 2014) explaining the lack of infection in this species.
Others
Even though rabies pathogenesis is mostly studied in dogs,
raccoons, or foxes, the protective efﬁcacy of a commercial, inacti-
vated rabies vaccine has also been demonstrated in ferrets
(Rupprecht et al., 1990). In the context of a pathogenesis study,
experimentally infected ferrets were assessed for susceptibility,
incubation period, morbidity, clinical signs, seroconversion, and
virus shedding. Interestingly, 17 out of 55 ferrets survived the
infection, and rabies virus was isolated only from one of these
animals (Niezgoda et al., 1997). Survival of ferrets experimentally
infected with rabies virus was also reported in a different study
(Hamir et al., 2011), indicating that they might be more resistant
than other carnivores. Ferrets were also used to characterize newly
discovered lyssaviruses with zoonotic potential and to evaluate the
efﬁcacy and cross-protection of available rabies vaccines (Hanlon
et al., 2005; Vos et al., 2004).
The potential of ferrets as an animal model has been evaluated
for other viral diseases, including mumps virus, simian virus 5,
canine or human parainﬂuenza viruses, and rubella virus. Two
recent studies demonstrated that mumps virus-infected ferrets
mounted robust humoral and cellular immune response but
developed no clinical signs and no virus was shed, indicating that
the use of the model is limited (Parker et al., 2013; Xu et al.,
2013a). Ferrets infected with simian virus 5 or canine and human
parainﬂuenza viruses, which generally cause a mild and transient
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disease in their natural hosts, develop antibody responses and
histopathological changes indicative of an infection in the upper
respiratory tract similar to those seen in other species, and may
thus be an attractive model for the development of vaccines or
antivirals (Capraro et al., 2008; Durchfeld et al., 1991; Mascoli
et al., 1976, 1975). Finally, during the late sixties, the use of ferrets
as an animal model for neonatal rubella was explored but this was
ultimately unsuccessful (Elizan et al., 1969; Fabiyi et al., 1967;
Rorke et al., 1968).
Conclusion
Ferrets have been used as animal models in viral research since
the beginning of the 20th century, starting with inﬂuenza and, as
their susceptibility for human respiratory viruses became increas-
ingly apparent, followed by an ever increasing number of additional
pathogens (Table 1). Even though their housing requirements are
more elaborate than those for rodents, ferrets can still be accom-
modated in most animal facilities, and animals can be purchased
from several commercial sources. The greatest disadvantage of the
ferret as an animal model remains the relative lack of species-speciﬁc
reagents. Although international efforts have been made to improve
this situation by generating ferret-speciﬁc tools and by identifying
cross-reactive reagents (Fang et al., 2010; Rutigliano et al., 2008),
ferret immune responses are still poorly characterized. In addition,
the potential of the model to characterize the contribution of opp-
ortunistic infections and different routes of inoculation, the dynamics
of aerosol transmission, and infections in the context of immuno-
suppression or co-morbidities is just beginning to be explored (Belser
et al., 2014; Gustin et al., 2013; Huber and McCullers, 2006; Koster
et al., 2012; McCullers et al., 2010; Peltola et al., 2006). Because of
its great public health relevance, most of the studies to date have
focused on inﬂuenza viruses, but an extension to other pathogens is
likely to follow in the near future.
The completion of the ferret genome and the publication of the
ferret transcriptome (Bruder et al., 2010; Peng et al., 2014) also
open new avenues of experimentation. Not only is it possible to
identify transcribed mRNA or activated genes at a given time point
of any viral infection, but the ferret genome information also
facilitates the development of species-speciﬁc genomic and pro-
teomic tools and the mapping of signaling pathways. After
succeeding with somatic cell nuclear transfer (Li et al., 2006),
the CFTR-knockout ferret as a cystic ﬁbrosis model (Sun et al.,
2010) provided proof-of-concept for the generation of transgenic
animals with speciﬁc phenotypes, and technical advances in the
transgenics ﬁeld such as the use of sleeping beauty transposons
(Ivics et al., 2014) and the CRISPR-Cas system (Hai et al., 2014; Tang
et al., 2015), will put transgenic ferrets within the reach of the
infectious disease research community. As new viruses continue to
emerge and additional immunologic, genomic, and proteomic
tools for ferrets become available, the importance of this animal
model for infectious disease research will likely continue to
increase.
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